
AACR 2025: High Response Rates With Dostarlimab Suggest New Standard for dMMR Treatment
Dostarlimab (Jemperli; GSK) yielded complete tumor clearance, resolving the need for surgery, in patients with locally advanced, mismatch repair-deficient (dMMR) cancer. The data from a phase 2 trial (NCT04165772) were presented at the American Association …